Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
Abstract Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD with swollen/tender joint counts (SJC/TJC) at basel...
Main Authors: | Philip Mease, Désirée van der Heijde, Bruce Kirkham, Georg Schett, Ana-Maria Orbai, Christopher Ritchlin, Joseph F. Merola, Luminita Pricop, David A. James, Xuan Zhu, Gregory Ligozio |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-022-02944-1 |
Similar Items
-
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
by: Christopher T. Ritchlin, et al.
Published: (2023-01-01) -
Radiographic assessment in rheumatoid arthritis: From daily practice to clinical trials
by: Corina Mogosan, et al.
Published: (2021-03-01) -
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
by: Désirée van der Heijde, et al.
Published: (2020-02-01) -
Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
by: Eleni Kampylafka, et al.
Published: (2018-07-01) -
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Laura C. Coates, et al.
Published: (2019-12-01)